UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATIONPurchase Agreement • March 2nd, 2020 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
On February 28, 2020, Aptevo Therapeutics Inc. (“Aptevo” or the “Company”) entered into an LLC Purchase Agreement (the “Purchase Agreement”) with Medexus Pharma, Inc. (“Medexus”), pursuant to which Aptevo sold all of the issued and outstanding limited liability company interests of Aptevo BioTherapeutics LLC (“Aptevo BioT”), a wholly owned subsidiary of Aptevo (the “Sale”). On the same date, the closing under the Purchase Agreement occurred. As a result of the Sale, Medexus acquired IXINITY (coagulation factor IX (recombinant)), a third-generation recombinant human coagulation factor IX marketed in the United States for the control and prevention of bleeding episodes and for perioperative management in adults and children 12 years of age or older with hemophilia B (the “IXINITY Business”).
ContractLLC Purchase Agreement • March 2nd, 2020 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS LLC PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of February 28, 2020, by and between: MEDEXUS PHARMA, INC., (“Purchaser”), a Delaware corporation and APTEVO THERAPEUTICS INC. (“Seller”), a Delaware corporation. Certain capitalized terms used in this Agreement are defined in Exhibit A.
